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Abstract
In the HPTN 052 study, transmission between HIV-discordant couples was reduced by 96% when the HIV-infected partner
received suppressive antiretroviral therapy (ART). We examined two transmission events where the newly infected partner
was diagnosed after the HIV-infected partner (index) initiated therapy. We evaluated the sequence complexity of the viral
populations and antibody reactivity in the newly infected partner to estimate the dates of transmission to the newly
infected partners. In both cases, transmission most likely occurred significantly before HIV-1 diagnosis of the newly infected
partner, and either just before the initiation of therapy or before viral replication was adequately suppressed by therapy of
the index. This study further strengthens the conclusion about the efficacy of blocking transmission by treating the infected
partner of discordant couples. However, this study does not rule out the potential for HIV-1 transmission to occur shortly
after initiation of ART, and this should be recognized when antiretroviral therapy is used for HIV-1 prevention.
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Introduction
Combination antiretroviral therapy (ART) reduces HIV-1 RNA
levels in blood and genital secretions [1,2,3]. The probability of
HIV-1 transmission is related to HIV-1 RNA levels in the plasma
[4,5] and the genital tract [6]. For these reasons, it seemed likely
that treatment of an infected person with ART would reduce
transmission to a sexual partner. Several observational studies
supported this idea [7,8,9,10]. The HPTN 052 study was
specifically designed to measure the degree to which suppressive
treatment of an HIV-infected person in a discordant relationship
could prevent sexual transmission [4]. In HPTN 052, HIV-
infected partners (index) with CD4+ T cell counts .350 and ,550
cells/ul, were randomized to receive immediate ART (early ART
arm), or to receive ART when their CD4+ T cell count dropped to
.200 and ,250 cells/ul (delayed ART arm). The study was
unblinded in April, 2011. At that time, 27 of 28 virologically-
linked transmission events [11] were found to have occurred in the
delayed ART arm, demonstrating a greater than 96% reduction in
HIV-1 transmission over a median of 1.7 years, ascribed to early
ART initiation. However, two transmission events raised the
possibility that transmission might still occur after ART initiation:
one virologically-linked transmission event in the early ART arm
(Case A, 052–1168), and one virologically-linked transmission
event in the delayed ART arm that occurred after the index
initiated ART in response to a falling CD4+ T cell count (Case B,
052–2899) [11]. We evaluated the timing of HIV-1 transmission in
these two cases by analyzing the viral sequence complexity and
antibody response in the newly infected partners.
Materials and Methods
Ethics statement
This research was performed with appropriate IRB approval
which was obtained from 36 different reviewing entities, included
in Supporting Information S1. Written informed consent was
provided, by all participants.
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Plasma samples were collected in the HPTN 052 study.
Methods used in the trial for HIV-1 diagnosis and HIV-1 viral
load testing were described previously [4]. The extent of
maturation of the antibody response was determined by examining
the pattern of reactivity with viral proteins in ELISA and western
blot format assays; antibody reactivity was interpreted using the
timing scale described in Fiebig et al. [12].
HIV-1 RNA was extracted from the plasma samples using the
QIAamp Viral RNA Mini Kit (QIAGEN), and was reverse
transcribed to produce cDNA using Superscript III Reverse
Transcriptase (Invitrogen) and an oligo dT primer. Polymerase
Chain Reaction (PCR) amplicons were generated from single
cDNA templates using an endpoint dilution strategy [13]; primers
were tailored for amplification of the env gene from subtype C
HIV-1, since both transmission events involved subtype C virus
[11]. For each sample, approximately 20 full-length env amplicons
were generated.
Sequences obtained from those amplicons were used to generate
phylogenetic trees using the program BEAST (Bayesian Evolu-
tionary Analysis by Sampling Trees) [14]. BEAST uses a Bayesian
Markov Chain Monte Carlo approach, implemented using the
program BEAST v.1.6.1 [14], which was used to estimate the time
Figure 1. Timeline and summary of data estimating dates of transmission relative to the initiation of therapy. A. A timeline (in days) is
shown relative to the date of initiation of therapy (D0) for both Case A and Case B. Dates are shown for the proximal time prior to therapy when the
viral load in the index was determined along with the proximal date after the initiation of therapy when the index had a viral RNA load below
400 copies/ml. Similarly, the date proximal to but before the date of initiation of therapy when the partner was HIV- (less than 40 copies/ml) and
when the partner was diagnosed by western blot analysis (WB) as being HIV+. B. Estimates of the date of transmission to the newly infected partner
are shown by the colored horizontal lines on the same timeline as in Panel A, shown separately for Case A and Case B. The gray background indicates
the period on therapy for the index. The small black vertical open boxes indicate the dates of the last HIV- sample from each partner, and these boxes
are preceded by a black vertical dashed line to indicate the eclipse period (7 days) when transmission could have occurred but not been detected in
the blood. The vertical red boxes indicate the dates of the first HIV+ sample in the partners. The horizontal lines represent the range of the possible
dates of transmission inferred using the several different approaches. The length of the horizontal line is meant to indicate the uncertainty associated
with the estimate. The vertical bar on the horizontal line represents the most likely date of transmission given the sequence diversity. Estimates for
the transmission date are shown for serology (in orange), sequence diversity using the Poisson Fitter (in purple), and for expansion of the sequence
population in the partner using BEAST (i.e. time to most recent common ancestor/MRCA; in dark blue). For the serology estimate we used the
shortest period of time needed for a newly infected person to progress to Fiebig Stage V (23 days) or Fiebig Stage VI) (55 days). Since an infected
person can stay in either of these stages for an extended period of time these lines are left-censored at the earliest possible transmission date (dashed
black vertical line) given the negative HIV-1 viral RNA load assay plus the eclipse period.
doi:10.1371/journal.pone.0071557.g001
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to the most recent common ancestor (MRCA) for each sample.
For Case A, this analysis was performed using just the major viral
population. We used a fixed mutation rate (1.561025) which we
have found useful in defining time since transmission for a number
of recent transmission events (unpublished data). We also used tip
dating given the known dates of sampling, which allowed an
output in days rather than generations. Accession numbers for the
env gene sequences used in the BEAST analysis are KC634109-
KC634205.
A second approach, the Poisson Fitter [15], was also used to
estimate the extent of early evolution in Case A. The Poisson Fitter
was implemented at http://www.hiv.lanl.gov/content/sequence/
POISSON_FITTER/poisson_fitter.html using the sequences
from the major viral population. A mutation rate of 2.1661025
per site per generation was used in the model.
Results and Discussion
First, we evaluated results obtained from HIV-1 RNA load
testing and Western blot testing for anti-HIV antibodies (note that
ART initiation is indicated as Day 0; negative numbers indicate
days before ART initiation and positive numbers indicate days
after ART initiation). In Case A, the partner had undetectable
HIV-1 RNA load (,40 copies/ml) at Day 235 and a positive
Western blot on Day +35 (Figure 1A). In Case B, the partner had
undetectable HIV-1 RNA load on Day 21 and a positive Western
blot on Day +84 (Figure 1A). Assuming a 7-day eclipse period
between HIV-1 infection and the detection of HIV-1 RNA in
plasma, transmission in Case A must have occurred after Day 242
(i.e., an outer limit of 7 days before the last negative sample), and
transmission in Case B must have occurred after Day 28.
Virologic suppression was first documented in the index at Day
+30 and Day +27 for Case A and B, respectively (Figure 1A). This
simple analysis indicates that transmission in both cases could have
Figure 2. Phylogenetic analysis of viral populations in the index and partner. The program BEAST was used to recreate phylogeny
(Bayesian skyline) of the viral env sequences generated from the index (black) and partner (red) for Case A (Panel A) and Case B (Panel B). Each tip
(with dot) of the tree is an individual sequence. For Case A, sequences from the partner are dispersed among the sequences from the index,
indicating the transmission of at least four variants (seen as four discrete positions in the tree where one or more red dots occur). For Case B, the
sequences from the partner represent a single lineage/cluster, indicative of transmission of a single variant. The tree structure moves back in time
from right to left as indicated by the arrow at the bottom and with the scale shown for 100 days. The tips of the tree are displaced to correspond to
the date the sample was taken that gave rise to those sequences. Each internal node/branch point in the tree represents the inferred most recent
common ancestor (MRCA) of all sequences that appear to the right of the node, with the position of each node given an estimated date from the
date the partner’s infection was detected. The dates (in days) of the MRCA within each partner (interpreted as the date expansion of the virus
population started after the transmission event) are indicated (40 days for Case A; 84 days for Case B), and the relevant nodes circled. The numbers in
small font indicate the estimated error in the dating of each node. The time to MRCA was estimated from two independent runs which were
combined, the HKY substitution model, estimated base frequencies, Gamma site heterogeneity model with 4 gamma categories, a strict clock with a
fixed mutation rate of 1.561025, partner tip dating, and the Bayesian skyline tree model.
doi:10.1371/journal.pone.0071557.g002
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occurred before ART was initiated, or after ART initiation but
before virologic suppression occurred.
The dates of transmission were defined further by analyzing
viral populations and the antibody response to infection in samples
from the newly infected partners to estimate the length of time the
newly infected partners had been infected. Viral populations were
analyzed using plasma samples collected from the index prior to
ART initiation (Case A: Day 238; Case B: Day 21) and plasma
samples collected from the newly infected partners on the day of
HIV-1 diagnosis (Case A: Day +35; Case B: Day +84).
Evaluation of transmission in Case A
In Case A, the partner was diagnosed with HIV-1 infection
35 days after the index initiated ART (Day +35). Phylogenetic
analysis of viral sequences from the index at Day 238 was
consistent with a chronic HIV-1 infection (i.e., a complex pattern
of HIV-1 variants with significant sequence diversity); in contrast,
phylogenetic analysis of viral sequences from the newly-infected
partner revealed one major population that was genetically
homogeneous and three minor viral populations indicating the
transmission of at least four variants (Figure 2A). The limited
genetic diversity in the major viral population from the newly
infected partner suggested that HIV-1 infection occurred close to
the time of HIV-1 diagnosis.
We used BEAST analysis [14] of the major viral population in
the newly-partner to estimate the number of days between HIV-1
infection (i.e. the number of days since this lineage existed as a
single sequence, referred to as the time to the most recent common
ancestor, MRCA) and HIV-1 diagnosis. The time to the MRCA
was estimated to be 40 days (95% CI: 25, 53 days, Table 1,
Figure 2A). This corresponds to an estimated transmission 5 days
before the index started ART (Day 22, 95% CI: Day –18, Day
+20).
We also used the Poisson Fitter Tool [15] to estimate the time
since transmission of the major population and HIV-1 diagnosis.
This tool estimates the number of viral generations based on the
accumulation of neutral mutations, which are observed before
selection on viral sequences by the host immune response [15].
With this tool, we estimated that the partner was infected 34 days
prior to HIV-1 diagnosis (95% CI: 22, 45 days, Table 1). This
corresponds to transmission one day after the index started ART
(Day +1, 95% CI: Day 210, Day +13), which is close to the
estimate provided by BEAST analysis.
As an independent measure of the timing of transmission, we
examined the HIV-1 antibody response in the newly infected
partner. In Case A, the antibody reactivity pattern in the Western
blot at the time of HIV-1 diagnosis was Fiebig Stage V [12],
displaying broad reactivity to viral proteins but without reactivity
to the integrase protein p31. This reactivity pattern appears after
Fiebig Stage IV, which lasts on average until 19 days, but can be
as short as 15 days after HIV-1 RNA is detectable in the blood, or
approximately 26 days, but as early a 22 days, after transmission
after including a 7-day eclipse period. Thus, Fiebig stage V can
start as early as 23 days after infection and persists on average
about 70 days. Based on these serologic findings, the newly
infected partner was likely to have been infected at least at least
23 days prior to HIV-1 diagnosis (Table 1); this corresponds to
transmission occurring on or before Day +12.
Figure 1B shows a summary of the time estimates associated
with this transmission event relative to the time of ART initiation
in the index (Day 0). In this case, data obtained from three
separate measures (sequence complexity using BEAST, sequence
complexity using Poisson Fitter, and serology) indicate that this
transmission event occurred significantly before HIV-1 diagnosis,
before or shortly after the index initiated ART.
Evaluation of transmission in Case B
In Case B, the partner was diagnosed with HIV-1 infection
84 days after the index initiated ART (Day +84). Phylogenetic
analysis of sequences from the index at Day 21 was consistent
with a chronic HIV-1 infection; in contrast, sequences from the
newly infected partner represented a single, monophyletic lineage,
consistent with transmission of a single HIV-1 variant (Figure 2B).
This population had a much higher level of diversity than the
major viral population in Case A, suggesting that a longer time
had elapsed between HIV-1 transmission and HIV-1 diagnosis in
Case B.
We used BEAST analysis to estimate the number of days
between HIV-1 infection and HIV-1 diagnosis in the newly
infected partner in Case B. The time to the MRCA was estimated
to be 84 days (95% CI: 65, 116 days, Table 1, Figure 2B). This
corresponds to transmission on the day the index started ART
(Day 0, 95% CI: Day 224, Day +19). It is unlikely the
transmission took place earlier than Day 28 given the negative
HIV-1 RNA test on Day 21, and the BEAST analysis is consistent
with transmission occurring prior to Day +19. In Case B, we did
not use the Poisson Fitter tool to provide an independent estimate
of the timing of transmission. This tool was designed to measure
the accumulation of neutral mutations that are observed before the
viral population is subjected to strong selective pressure. Given the
complexity of the sequences in the newly infected partner in Case
B, we chose not to use Poisson Fitter.
We also examined the HIV-1 antibody response in the newly
infected partner. Consistent with the greater genetic complexity of
the population in this newly infected partner, results from antibody
reactivity in Western blot analysis suggested a more mature host
Table 1. Data obtained using BEAST analysis, the Poisson Fitter tool, and serological analysis are expressed as the number of days
between the estimated date of HIV-1 transmission and HIV-1 diagnosis in the newly-infected partner. These data are also shown in
Figure 1B, expressed as days before or after ART initiation in the index.
Subject HIV-1 Diagnosisa BEAST MRCA in Partner (95% HPD)b Poisson Fitter (95% CI)c Serology (earliest/average)d
Case A Day +35 40 (25, 53) 34 (22, 45) Fiebig stage V (23/27)
Case B Day +84 84 (65, 116) Not Applicable Fiebig stage VI (55/97)
aHIV-1 diagnosis indicates the number of days between ART initiation in the index and HIV-1 diagnosis in the partner (first HIV-positive sample).
bEstimate of the time between HIV-1 transmission and HIV-1 diagnosis in the newly-infected partner based on BEAST analysis.
cEstimate of the time between HIV-1 transmission and HIV-1 diagnosis in the newly-infected partner based on use of the Poisson Fitter (Case A only).
dThe table shows the earliest and average number of days between HIV-1 transmission and the Fiebig stage of each of the newly-infected partners, based on Western
blot analysis. The partner in Case A was Fiebig stage V; the partner in Case B was Fiebig Stage VI [12]; a 7-day eclipse period was included in the calculations.
doi:10.1371/journal.pone.0071557.t001
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immune response. The reactivity pattern for this partner was
consistent with Fiebig Stage VI, reflecting the presence of anti-
HIV antibodies that included reactivity to the p31 integrase
protein. On average, reactivity to p31 does not appear until
90 days after HIV-1 RNA is detectable, but can appear as early as
48 days after HIV-1 RNA detection. Assuming a 7-day eclipse
period, the finding of Fiebig stage VI reactivity in this participant
indicates that transmission could have occurred as early as 55 days
before HIV-1 diagnosis (Table 1), or Day +29. Transmission could
have occurred even before this date since Fiebig Stage VI
represents the terminal stage in this scale. These serologic findings
are consistent with findings based on viral genetic analysis.
Data obtained for Case B are summarized in Figure 1B. In this
case, as in Case A, it is most likely that HIV-1 transmission
occurred either before ART initiation, or shortly after ART
initiation. However, the longer time interval between ART
initiation in the index and HIV-1 diagnosis in the partner
(84 days, compared to 35 days in Case A) adds an increased level
of uncertainty in estimating the timeframe within which transmis-
sion occurred.
Conclusions
The HPTN 052 study provided unequivocal evidence that ART
can prevent HIV-1 transmission [4]. This has led to substantial
changes in public policy (www.pepfar.gov/documents/
organization/177126.pdf) and has inspired several studies to
determine the population level effects of ART for prevention.
Results from the HPTN 052 study will determine the durability of
ART for prevention. In this report, we demonstrate that two HIV-
1 transmission events in HPTN 052 that were documented after
the index initiated ART most likely occurred either shortly before
ART initiation or before ART could sufficiently suppress viral
replication in the genital tract. Combination antiretroviral therapy
still requires several weeks for suppression of HIV-1 in blood [2].
These results indicate that HIV-infected patients beginning ART
should be informed that several weeks of ART may be needed
before the risk of HIV-1 transmission is significantly reduced [4].
Documentation that these two transmission events were likely to
have occurred before or shortly after ART initiation (prior to
virologic suppression) provides further evidence of the efficacy of
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